Korsana Biosciences, Inc.
No trades
No trades
Peers for comparison
−13.07 USD
−3.53 M USD
2.07 M USD
44.96 M
Last report date
Report period
EPS
Revenue
Company info
Sector
Industry
CEO
Jonathan Violin
Website
Headquarters
Waltham
Founded
2024
ISIN
US23255M3034
CUSIP
23255M303
FIGI
BBG00KXXHYD9
Identifiers
ISIN US23255M3034
Korsana Biosciences, Inc. is a biopharmaceutical company, which engages in discovering and developing novel therapies to reduce the burden of neurodegenerative diseases. Its portfolio includes the KRSA-028 pipeline. The company was founded in 2024 and is headquartered in Waltham, MA.
Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral
An aggregate view of professional's ratings.
Neutral
Neutral
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
Today, KRSA trades at 31.84 USD.
For broader market analysis, dive into the technicals on the Korsana Biosciences, Inc. stock price chart and read the latest KRSA news:
– KRSA: KRSA-028 targets monthly subQ dosing, with first patient proof-of-concept due by Q1 2028
– KRSA: KRSA-028 aims to pair brain-shuttled plaque clearance with monthly subcutaneous dosing
– Korsana Biosciences 3Q 2026: EPS ($3.19) — 10-Q Summary
For broader market analysis, dive into the technicals on the Korsana Biosciences, Inc. stock price chart and read the latest KRSA news:
– KRSA: KRSA-028 targets monthly subQ dosing, with first patient proof-of-concept due by Q1 2028
– KRSA: KRSA-028 aims to pair brain-shuttled plaque clearance with monthly subcutaneous dosing
– Korsana Biosciences 3Q 2026: EPS ($3.19) — 10-Q Summary
Markets don't sleep, here's what's going on with KRSA at the moment:
– KRSA: KRSA-028 targets monthly subQ dosing, with first patient proof-of-concept due by Q1 2028
– KRSA: KRSA-028 aims to pair brain-shuttled plaque clearance with monthly subcutaneous dosing
– Korsana Biosciences 3Q 2026: EPS ($3.19) — 10-Q Summary
See more updates in real-time with our News Flow.
– KRSA: KRSA-028 targets monthly subQ dosing, with first patient proof-of-concept due by Q1 2028
– KRSA: KRSA-028 aims to pair brain-shuttled plaque clearance with monthly subcutaneous dosing
– Korsana Biosciences 3Q 2026: EPS ($3.19) — 10-Q Summary
See more updates in real-time with our News Flow.
Korsana Biosciences, Inc. is scheduled to release its next earnings report on Mar 24, 2027.
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
KRSA stock is 7.06% volatile and has beta coefficient of 5.92.
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like KRSA are typically less volatile than smaller companies
Track every detail on Korsana Biosciences, Inc. stock chart and check out the list of the most volatile stocks — is Korsana Biosciences, Inc. there?
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like KRSA are typically less volatile than smaller companies
Track every detail on Korsana Biosciences, Inc. stock chart and check out the list of the most volatile stocks — is Korsana Biosciences, Inc. there?
To understand the KRSA stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — +3.83%
– 1 week — +1.40%
– 1 month — −5.69%
KRSA all-time low was 7.19 USD (Feb 9, 2026), and its highest price is 3,199.00 USD (Apr 1, 2019). Find more dynamics in the Stock Heatmap and on the Korsana Biosciences, Inc. stock chart.
– 1 day — +3.83%
– 1 week — +1.40%
– 1 month — −5.69%
KRSA all-time low was 7.19 USD (Feb 9, 2026), and its highest price is 3,199.00 USD (Apr 1, 2019). Find more dynamics in the Stock Heatmap and on the Korsana Biosciences, Inc. stock chart.
Korsana Biosciences, Inc. market capitalization is 1.42 B, representing the total value of all its outstanding shares (price × shares outstanding).
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Korsana Biosciences, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Korsana Biosciences, Inc. stacks up against other companies
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Korsana Biosciences, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Korsana Biosciences, Inc. stacks up against other companies
The safest way to buy Korsana Biosciences, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.
You can trade KRSA directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
You can trade KRSA directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
As of Nov 12, 2026, the company has 1 employees.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Investing in Korsana Biosciences, Inc. depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.
First, study Korsana Biosciences, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our KRSA technicals – signals based on essential indicators calculations:
– Today — strong buy
– 1-week — buy
– 1-month — buy
Combine fundamental and technical analysis for better results.
First, study Korsana Biosciences, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our KRSA technicals – signals based on essential indicators calculations:
– Today — strong buy
– 1-week — buy
– 1-month — buy
Combine fundamental and technical analysis for better results.
Korsana Biosciences, Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Korsana Biosciences, Inc. stocks trade under the symbol KRSA.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
KRSA earnings for the last quarter are −3.19 USD per share, whereas the estimation was −0.85 USD, resulting in a −276.64% surprise. The estimated earnings for the next quarter are −0.90 USD per share.
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Korsana Biosciences, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Korsana Biosciences, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
Korsana Biosciences, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
What it might mean:
– Stable demand: Sales are holding steady without clear growth or decline
– Mature business phase: Growth may be slowing in core segments
– Offsetting factors: Strength in some areas may be balancing weakness in others
What to look at next in Korsana Biosciences, Inc. financials:
– Margins: Profitability may improve or decline even if revenue is flat
– Net income & EPS: Cost control or share buybacks can still drive earnings changes
– Segment breakdown: Some business lines may be growing while others shrink
What it might mean:
– Stable demand: Sales are holding steady without clear growth or decline
– Mature business phase: Growth may be slowing in core segments
– Offsetting factors: Strength in some areas may be balancing weakness in others
What to look at next in Korsana Biosciences, Inc. financials:
– Margins: Profitability may improve or decline even if revenue is flat
– Net income & EPS: Cost control or share buybacks can still drive earnings changes
– Segment breakdown: Some business lines may be growing while others shrink
Yes, you can track Korsana Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
KRSA net income for the last quarter is −46.42 M USD, while the quarter before that showed −1.75 M USD of net income which accounts for −2.55 K% change.
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Korsana Biosciences, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Korsana Biosciences, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
No, Korsana Biosciences, Inc. does not currently pay dividends to its shareholders.
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
KRSA reached its all-time high of 3,199.00 USD on Apr 1, 2019. Its all-time low was 7.19 USD and was reached on Feb 9, 2026.
Explore the Korsana Biosciences, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Explore the Korsana Biosciences, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Korsana Biosciences, Inc. EBITDA is −54.06 M USD, with an EBITDA margin of −239.78%.
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Korsana Biosciences, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Korsana Biosciences, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
Analyst forecasts suggest a price range between 43.00 USD and 70.00 USD for KRSA, based on current estimates.
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance